Bone health and vascular calcification relationships in chronic kidney disease

International Urology and Nephrology

Volumn 39, Issue 4, 2007, Pages 1209-1216

  Spasovski, Goce B ^a  

^a University Clinical Center Skopje   (Macedonia)

Author keywords

Adynamic bone disease; Calcium phosphate binder; Low dialysate calcium concentration; Secondary hyperparathyroidism; Vascular calcification

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; VITAMIN D; VITAMIN D DERIVATIVE;

ADYNAMIC BONE DISEASE; BLOOD VESSEL CALCIFICATION; BONE BIOPSY; BONE DISEASE; BONE METABOLISM; BONE MINERALIZATION; BONE TURNOVER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DIET RESTRICTION; DRUG SAFETY; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY FUNCTION; MINERAL DEFICIENCY; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RENAL OSTEODYSTROPHY; REVIEW; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; TRABECULAR BONE;

BONE DISEASES; CALCIUM; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; HYPOPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; PHOSPHATES;

EID: 36649017661     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-007-9276-9     Document Type: Review

References (67)

1. Moe S, Drueke T, Cunningham J et al (2006) Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945-1953
2. Llach F, Coburn JW (1989) Renal osteodystrophy and maintenance dialysis. In: Maher JF (ed) Replacement of renal function by dialysis, Kluwer, Dordrecht, pp 911-952
3. Spasovski G, Bervoets A, Behets G et al (2003) Spectrum of renal bone disease in end-stage renal failure patients not in dialysis yet. Nephrol Dial Transplant 18:1159-1166
4. Spasovski GB (2004) Bone biopsy as a diagnostic tool in the assessment of renal osteodystrophy. Int J Artif Organs 27:918-923
5. Salusky IB, Coburn JW, Brill J et al (1988) Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 33:975-982
6. Slatopolsky E, Finch J, Denda M et al (1996) Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97:2534
7. Salusky IB, Foley J, Nelson P, Goodman WG (1991) Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 324:327
8. Quarles LD, Davidai GA, Schwab SJ et al (1988) Oral calcitriol and calcium: Efficient therapy for uremic hyperparathyroidism. Kidney Int 34:840
9. Goodman WG (1985) Bone disease and aluminum: Pathogenic considerations. Am J Kidney Dis 6:330-335
10. Torres A, Lorenzo V, Hernandez D (1995) Bone disease in predialysis, hemodialysis and CAPD patients: Evidence for a better response to PTH. Kidney Int 47:1434-1442
11. Sherrard DJ, Hercz G, Pei Y et al (1993) The spectrum of bone disease in end-stage renal failure'an evolving disorder. Kidney Int 43:436-442
12. Akizawa T, Kinugasa E, Kurihara S (1999) Parathyroid hormone deficiency is an indicator of poor nutritional state and prognosis in dialysis patients. J Am Soc Nephrol 10:616A
13. Pei Y, Hercz G, Greenwood C (1995) Risk factors for renal osteodystrophy. A multivariant analysis. J Bone Miner Res 10:149-156
14. Couttenye MM, D'Haese PC, Deng JT et al (1997) High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant 12:2144-2150
15. Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T, Kurokawa K, Fukagawa M (2005) Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid. Nephrol Dial Transplant 20:1904-1911
16. Disthabanchong S, Hassan H, Mcconkey CL, Martin KJ, Gonzalez EA (2004) Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 106-01 osteoblast-like cells. Kidney Int 65:897-903
17. Hutchison AJ, Whitehouse RW, Boulton HF et al (1993) Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 44:1071-1077
18. Shin SK, Kim DH, Kim HS et al (1999) Renal osteodystrophy in pre-dialysis patients: Ethnic difference? Perit Dial Int 19(Suppl 2):S402-S407
19. D'Haese PC, Spasovski G, Sikole A et al (2003) Multi-centre study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 63(Suppl 85):S73-S78
20. Coco M, Rush H (2000) Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36:1115-1121
21. Goodman WG, Goldin SJ, Kuizon BD (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483
22. Braun J, Oldendorf M, Moshage W et al (1996) Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27:394-401
23. Eknoyan G, Lameire N, Barsoum R et al (2004) The burden of kidney disease: Improving global outcomes. Kidney Int 66:1310-1314
24. Block GA, Cunningham J (2006) Morbidity and mortality associated with abnormalities in bone and mineral metabolism in CKD. In: Olgaard K (ed) Clinical guide to the basics of bone and mineral metabolism in CKD. National Kidney Foundation, New York, pp 77-92
25. London G, Drueke T (1997) Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 51:1678-1695
26. Foley RN, Parfrey PS, Sarnak MJ et al (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112-S119
27. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938-942
28. Qunibi WY (2005) Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Kidney Int 95(Suppl):S43-S50
29. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL (1994) High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 93:2393-2402
30. Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME (1999) Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: Evidence for smooth muscle cell-mediated vascular calcification. Circulation 100:2168-2176
31. Shanahan CM (2005) Vascular calcification. Curr Opin Nephrol Hypertens 14:361-367
32. Martin KJ, Gonzalez EA (2001) Strategies to minimize bone disease in renal failure. Am J Kidney Dis 38:1430-1436
33. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A (2004) Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15:770-779
34. Neves KR, Graciolli FG, dos Reis LM et al (2007) Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 71:1262-1270
35. Price PA, Faus SA, Williamson MK (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21:817-824
36. Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R et al (2004) Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44:680-688
37. Block GA, Martin KJ, de Francisco AL et al (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525
38. Salusky IB, Goodman WG (2001) Adynamic renal osteodystrophy: Is there a problem? J Am Soc Nephrol 12:1978-1985
39. Kurz P, Monier-Faugere MC, Bognar B et al (1994) Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46:855-861
40. London GM, Marty C, Marchais SJ et al (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15:1943-1951
41. Levin NW, Hoenich NA (2001) Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients. Curr Opin Nephrol Hypert 10:563-568
42. Young EW, Akiba T, Albert JM et al (2004) Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44(Suppl 3):34-38
43. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218
44. Jono S, McKee MD, Murry CE et al (2000) Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:E10-E17
45. Reynolds JL, Joannides AJ, Skepper JN et al (2004) Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extra-cellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15:2857-2867
46. Moe SM (2006) Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 36(Suppl 2):51-62
47. Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617
48. Young EW, Albert JM, Satayathum S et al (2005) Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 67:1179-1187
49. Kimura K, Saika Y, Otani H, Fujii R, Mune M, Yukawa S (1999) Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int 56(Suppl. 71):S238-S241
50. Slatopolsky E, Finch J, Denda M et al (1996) Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97:2534-2540
51. Mucsi I, Hercz G, Uldall R et al (1998) Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 53:1399-1404
52. De Broe ME, Coburn JW (1990) Aluminum and renal failure. In: Developments in Nephrology, vol 26. Kluwer Dordrecht, pp 99-375
53. Guerin AP, London GM, Marchais SJ, Metivier F (2000) Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15:1014-1021
54. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H (2003) Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731-1740
55. Hsu CH (1997) Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 29:641-649
56. Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252
57. Suresh M, Richard JL, Frank S et al (2007) Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 18:122-130
58. Raggi P, James G, Burke SK et al (2005) Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 20:764-772
59. Spasovski GB, Gelev S, Sikole A, Masin-Spasovska J et al (2006) Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1-year treatment with lanthanum carbonate and after two years of follow up. Nephrol Dial Transplant 532:2217-2224
60. Vanholder R, Massy Z, Argiles A, Spasovski G et al (2005) Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20:1048-1056
61. Zoccali C (2006) Traditional and emerging cardiovascular and renal risk factors: An epidemiologic perspective. Kidney Int 70:26-33
62. Huybrechts KF, Caro JJ, Wilson DA, O'Brien JA (2005) Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 8:549-561
63. Nolan CR (2005) Strategies for improving long-term survival in patients with ESRD. J Am Soc Nephrol 16(Suppl 2):S120-S127
64. Joy MS, Karagiannis PC, Peyerl FW (2007) Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm 13:397-411
65. Haris A, Sherrard DJ, Hercz G (2006) Reversal of adynamic bone disease by lowering of dialysate calcium. Kidney Int 70:931-937
66. Spasovski G, Gelev S, Masin-Spasovska J et al (2007) Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. Bone 41:698-703
67. K/DOQI, NKF (2003) Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1-S201